2. Search Result
Search Result
Results for "

Antiviral inhibitor

" in MedChemExpress (MCE) Product Catalog:

1023

Inhibitors & Agonists

4

Screening Libraries

3

Fluorescent Dyes

12

Biochemical Assay Reagents

23

Peptides

4

Inhibitory Antibodies

192

Natural
Products

50

Isotope-Labeled Compounds

15

Click Chemistry

10

Oligonucleotides

2

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14809
    Amenamevir
    5+ Cited Publications

    ASP2151

    		 HSV Infection
    Amenamevir is a helicase-primase inhibitor which has potent antiviral activity against HSVs with an EC50 of 14 ng/mL.
    Amenamevir
  • HY-156654
    Ibuzatrelvir
    1 Publications Verification

    PF-07817883

    		 SARS-CoV Virus Protease Infection
    Ibuzatrelvir (PF-07817883), a second-generation, orally bioavailable, is SARS-CoV-2 main protease (M pro and 3CL pro) inhibitor with improved metabolic stability. Ibuzatrelvir has demonstrated pan-human coronavirus antiviral activity and off-target selectivity profile in vitro and in preclinical animal studies. Ibuzatrelvir is well tolerated with a safety profile similar to placebo and prevents viral infection and transmission. Ibuzatrelvir can be used to inhibit COVID-19 .
    Ibuzatrelvir
  • HY-I0660
    Picolinic acid
    1 Publications Verification

    PCL 016

    		 MOFs Endogenous Metabolite Virus Protease Infection
    Picolinic acid (PCL 016) is a topical antiviral agent, which inhibits adenovirus replication in rabbits.
    Picolinic acid
  • HY-152851
    Izumerogant

    IMU-935

    		 ROR Dihydroorotate Dehydrogenase SARS-CoV CMV Infection
    Izumerogant (IMU-935) is an orally active RORγ/DHODH dual inhibitor with IC50s of 10 and 98 nM against RORγ and DHODH. Izumerogant efficiently blocks the replication of SARS-CoV-2, HCMV and HAdV5 with EC50 values between 3.6 and 17 nM. Izumerogant can be used for researching antiviral properties .
    Izumerogant
  • HY-N6715
    Tenuazonic acid

    		Influenza Virus Bacterial Enterovirus Photosystem II Infection Cancer
    Tenuazonic acid is a nonhost-selective mycotoxin belonging to the tetramic acids family. Tenuazonic acid inhibits protein biosynthesis on ribosomes by suppressing the release of new protein. Tenuazonic acid is acutely toxic, and oral LD50 is set between 81-186 mg/kg in rats and mice. Tenuazonic acid blocks electron transport beyond the primary quinone receptor (QA) by interacting with the D1 protein and is a photosystem II (PSII) inhibitor. In addition, Tenuazonic acid has antiviral effects on measles virus, enterovirus, respiratory virus and so on. Tenuazonic acid has an inhibitory effect on skin cancer .
    Tenuazonic acid
  • HY-114275
    Justicidin B

    		Fungal Parasite Apoptosis Infection Cardiovascular Disease Cancer
    Justicidin B is a potent anticancer lignan and proapoptotic agent. Justicidin B is also a bone resorption inhibitor, and has strong antiviral, fungicidal, antiprotozoal effects. Justicidin B significantly inhibits platelet aggregation .
    Justicidin B
  • HY-138078
    Lufotrelvir
    2 Publications Verification

    PF-07304814

    		 SARS-CoV Infection
    Lufotrelvir (PF-07304814), a phosphate proagent of PF-00835231, acts as a potent 3CLpro protease (Mpro) inhibitor with SARS-CoV-2 antiviral activity. Lufotrelvir binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174nM. Lufotrelvir is promising single antiviral agent and also can be used for the research of combination with other antivirals that target other critical stages of the coronavirus life cycle.
    Lufotrelvir
  • HY-16957
    LJ001

    		HCV HIV Infection
    LJ001 is a broad-spectrum and orally active antiviral agent. LJ001 exerts antiviral activities by binding to viral membranes. LJ001 inhibits TGEV and PDCoV infection. LJ001 decreases TGEV N and PDCoV N-protein expression .
    LJ001
  • HY-W013441
    2',3'-Dideoxyadenosine
    1 Publications Verification

    		 HIV Infection
    2',3'-Dideoxyadenosine is an inhibitor of HIV replication . Antiretroviral activity . Antiviral efficacy .
    2',3'-Dideoxyadenosine
  • HY-148852
    PNU-183792

    		HSV Infection
    PNU-183792, a 4-oxo-dihydroquinoline, is an orally active HSV polymerases inhibitor. PNU-183792 shows a broad-spectrum antiviral activity, with IC50 values of 0.69 μM, 0.37 μM and 0.58 μM for human cytomegalovirus (HCM), varicella zoster virus and HSV polymerases, respectively. PNU-183792 is inactive against human α, γ and δ polymerases. PNU-183792 also inhibits simian varicella virus (SVV), murine cytomegalovirus (MCMV) and rat cytomegalovirus (RCMV) .
    PNU-183792
  • HY-150737
    MI-1851

    		SARS-CoV Infection
    MI-1851 is a potent furin inhibitor. MI-1851 prevents the proteolytic processing of the S protein of SARS-CoV-2 by endogenous flavoprotease in HEK293 cells. MI-185 has antiviral activity .
    MI-1851
  • HY-163943
    UNI418

    		SARS-CoV PIKfyve Infection
    UNI418 is a dual inhibitor of PIKfyve and PIP5K1C with antiviral activity against SARS-CoV-2 (EC50=1.4 μM). UNI418 blocks ACE2-mediated SARS-CoV-2 viral endocytosis by inhibiting PIP5K1C (IC50=60.1 nM; Kd=61 nM). In addition, UNI418 inhibits the proteolytic activation of proteases regulated by PIKfyve (Kd=0.78 nM) to prevent SARS-CoV-2 from entering host cells .
    UNI418
  • HY-177303
    AXT-914

    		CaSR SARS-CoV Infection Metabolic Disease Endocrinology
    AXT-914 is a Calcium-sensing receptor (CaSR) inhibitor. AXT-914 has antiviral activity against the coronavirus HCoV 229E and SARS-CoV2. AXT914 reduces cytosolic calcium signalling activity of CaSR mutations. AXT-914 can be used for Bartter syndrome type 5 and autosomal dominant hypocalcemia (ADH) and coronavirus infections research .
    AXT-914
  • HY-168738
    Limnetrelvir

    		SARS-CoV Virus Protease Infection
    Limnetrelvir (ABBV-903) is a MPro inhibitor. Limnetrelvir could be used in antiviral research .
    Limnetrelvir
  • HY-157478
    CSNK2A-IN-1

    		Casein Kinase Infection
    CSNK2A-IN-1 (compound 7C) is a selective CSNK2A inhibitor. CSNK2A-IN-1 has antiviral activity and improved selectivity over PIM3 .
    CSNK2A-IN-1
  • HY-176264
    DNDI-6510

    		SARS-CoV Virus Protease Cytochrome P450 Infection
    DNDI-6510 (Compound (S)-x38) is a non-covalent SARS-CoV-2 MPro inhibitor with a IC50 of 0.04 μM. DNDI-6510 has a potent antiviral activity across SARS-CoV-2 and its variants as well as a weak efficacy to SARS-CoV-1. DNDI-6510 significantly improves drug exposure in metabolically humanized mice model (8HUM) .
    DNDI-6510
  • HY-P11032
    Mp-4D7-pF2

    		SARS-CoV Virus Protease Infection
    Mp-4D7-pF2, a cell-penetrating bicyclic peptide, is a noncovalent SARS-CoV-2 main protease inhibitor with an IC50 of 4.51 μM. Mp-4D7-pF2 has an antiviral activity against SARS-CoV-2 with no cytotoxicity. Mp-4D7-pF2 can used for COVID-19 infections research .
    Mp-4D7-pF2
  • HY-131976
    BVDV-IN-1

    		Flavivirus Infection
    BVDV-IN-1 is a non-nucleoside inhibitor (NNI) of bovine viral diarrhea virus (BVDV), with an EC50 of 1.8 μM. BVDV-IN-1 directly binds to a hydrophobic pocket of the BVDV RdRp. BVDV-IN-1 has antiviral activity against BVDV resistant to NNI thiosemicarbazone (TSC) .
    BVDV-IN-1
  • HY-N7934
    Trachelogenin

    (-)-Trachelogenin

    		 HCV Infection Neurological Disease Inflammation/Immunology
    Trachelogenin ((-)-Trachelogenin) is an HCV entry inhibitor without genotype specificity, and with low cytotoxicity. Trachelogenin inhibits HCVcc infection and HCVpp cell entry in a dose-dependent manner with an IC50 of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively. Trachelogenin exhibits effective antiviral, anti-inflammatory and analgesic effects .
    Trachelogenin
  • HY-144623
    Antiviral agent 15

    		SARS-CoV Infection
    Antiviral agent 15 (Compound 15f) is a Clofazimine derivative with antiviral effects. Antiviral agent 15 inhibits both rabies virus and pseudo-typed SARS-CoV-2 with EC50 values of 1.45 μM and 14.6 μM, respectively .
    Antiviral agent 15
  • HY-179691
    Antiviral agent 75

    		Filovirus Infection
    Antiviral agent 75 (example D26) is a Ebolavirus (EBOV) and Bundibugyo ebolavirus (BDBV) inhibitor with IC50s of 0.11 μM and 0.75 μM, respectively. Antiviral agent 75 can be used for the study of filovirus infection .
    Antiviral agent 75
  • HY-175536
    AAK1-IN-11

    		AAK1 Infection
    AAK1-IN-11 is an AAK1 (adaptor associated kinase 1) inhibitor with an IC50 of 2 nM. AAK1-IN-11 has antiviral activity .
    AAK1-IN-11
  • HY-158763
    MPI8

    TG0205221

    		 SARS-CoV Cathepsin Virus Protease Infection
    MPI8 (TG0205221) is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). MPI8 can be used in clinical studies of COVID-19 .
    MPI8
  • HY-150580
    CYP3A4-IN-2

    		Cytochrome P450 Inflammation/Immunology Cancer
    CYP3A4-IN-2 is a specific inhibitor of cytochrome P450 3A4 (CYP3A4) with the IC50 value of 0.055 μM. CYP3A4-IN-2 is a ritonavir analogue with increased hydrophobicity of the R2 side group and stronger inhibitory effect compared to ritonavir. CYP3A4-IN-2 can be used as an antiviral agent and immunosuppressants .
    CYP3A4-IN-2
  • HY-174303
    NNRT-IN-9

    		HIV Reverse Transcriptase Infection
    NNRT-IN-9 (Compound EG28) is a non-nucleoside reverse transcriptase (NNRT) inhibitor. NNRT-IN-9 has potent antiviral and anti-resistance activity against wild-type (WT) HIV-1 and various clinically relevant mutations (E138K and K103N + Y181C) with EC50s of 55, 67 and 3910 nM, respectively. NNRT-IN-9 can be used for acquired immune deficiency syndrome (AIDS) research .
    NNRT-IN-9
  • HY-175351
    HIV-1-IN-83

    		HIV Reverse Transcriptase Infection
    HIV-1-IN-83 (Compound 18E) is a HIV-1 non-nucleoside reverse transcriptase inhibitor with an IC50 of 0.45 μM for wild-type HIV-1 non-nucleoside reverse transcriptase. HIV-1-IN-83 has potent antiviral activity against both HIV-1 wild-type and mutant strains and improves antidrug resistance for Y188L and RES056 mutant strains. HIV-1-IN-83 has no significant toxicity up to 11.088 μM .
    HIV-1-IN-83
  • HY-174814
    Jun15716

    		Enterovirus Infection
    Jun15716 is an Enterovirus (EVs) 2C protein (EVs 2C) inhibitor with Kis of 15.9, 44.2 and 17.8 μM for EV-D68, EV-A71 and CVB3, respectively. Jun15716 has a potent antiviral activity against EV-D68 US/MO/14-18947 and CVB3 Nancy cells (EC50s of 1.0 and 0.7 μM, respectively). Jun15716 can be used for viral infections research, such as meningitis, hand, foot and mouth disease (HFMD) and viral myocarditis .
    Jun15716
  • HY-146418
    Antiviral agent 20

    		Flavivirus Infection
    Antiviral agent 20 (Compound 17b) is a selective inhibitor against Zika virus infection with an EC50 of 4.5 µM. Antiviral agent 20 has low cytotoxicity .
    Antiviral agent 20
  • HY-151926
    Antiviral agent 24

    		Enterovirus Infection
    Antiviral agent 24 is a potent antiviral agent with EC50 values of 0.101, 19.9, 91.2 µM for EV71, CVA21, EV68, respectively. Antiviral agent 24 inhibits METTL3/METTL14 activity in a dose-dependent manner .
    Antiviral agent 24
  • HY-106233
    Tiviciclovir

    AM188

    		 HBV Infection
    Tiviciclovir (AM188) is an antiviral guanosine analog and a hepatitis B virus inhibitor .
    Tiviciclovir
  • HY-N15215
    Antiviral agent 64

    		Enterovirus Influenza Virus RSV HSV Infection Cancer
    Antiviral agent 64 (Compound 12) is a diarylheptanoid that can be isolated from Alpinia officinarum. Antiviral agent 64 exhibits cytotoxicity in human neuroblastoma cell IMR-32 with an IC50 of 0.23 μM. Antiviral agent 64 exhibits antiviral efficacy, that inhibits RSV, poliovirus, measles virus, HSV-1, and influenza virus H1N1, with EC50 of 13.3, 3.7, 6.3, 5.7, and <10 μg/mL, respectively .
    Antiviral agent 64
  • HY-174815
    Jun15799

    		Enterovirus Infection
    Jun15799 is an Enterovirus (EVs) 2C protein (EVs 2C) inhibitor with Kis of 0.8, 21.1 and 3.0 μM for EV-D68, EV-A71 and CVB3, respectively. Jun15799 has a significant antiviral activity against EV-D68 US/MO/14-18947, EV-A71 Tainan/4643/1998 and CVB3 Nancy cells (EC50s of 0.3, 11.4 and 0.3 μM, respectively). Jun15799 can be used for viral infections research, such as meningitis, hand, foot and mouth disease (HFMD) and viral myocarditis .
    Jun15799
  • HY-137954
    GRL-0496

    		SARS-CoV Infection
    GRL-0496 is a potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitor, with an IC50 of 30 nM in both enzyme inhibitory and antiviral assays. GRL-0496 shows SARS-CoV antiviral activity, with an EC50 of 6.9 μM .
    GRL-0496
  • HY-12109
    L-870810

    		HIV Infection
    L-870810 is a potent HIV-1 IN chain transfer inhibitor with antiviral activity .
    L-870810
  • HY-131179
    Influenza A virus-IN-1

    		Influenza Virus Infection
    Influenza A virus-IN-1 is a dihydropyrrolidones derivative and is a potent inhibitor against wide subtypes of influenza A virus (IAV) with IC50 values from 3.11 μM to 7.13 μM. Influenza A virus-IN-1 efficiently inhibits replication of IAV, up-regulates the expression of key antiviral cytokines IFN-β and antiviral protein MxA .
    Influenza A virus-IN-1
  • HY-168987
    Netanasvir

    		HCV HCV Protease Infection Inflammation/Immunology
    Netanasvir, a NS5A inhibitor, possesses antiviral activity. Netanasvir can be used in the study for HCV study .
    Netanasvir
  • HY-155968
    HBV-IN-40

    		HBV Infection
    HBV-IN-40 (Compound 11826096) is a HBV inhibitor (IC50: 0.7 μM). HBV-IN-40 is an antiviral agent .
    HBV-IN-40
  • HY-169112
    HCV-IN-46

    		HCV Infection
    HCV-IN-46 (compound 6d) is a HCV inhibitor with an EC50 value of 3.717 μM. HCV-IN-46 has antiviral activity .
    HCV-IN-46
  • HY-175550
    HIV-1-IN-86

    		HIV Infection
    HIV-1-IN-86 (compound 6m) is a HIV-1 inhibitor with an EC50 of 0.77 μM. HIV-1-IN-86 has antiviral activity .
    HIV-1-IN-86
  • HY-169012
    PSB-21110

    		SARS-CoV Virus Protease Infection
    PSB-21110 is an irreversible SARS-CoV-2 Mpro inhibitor with EC50 value of 2.68 nM. PSB-21110 has antiviral activity .
    PSB-21110
  • HY-123608
    JE-2178

    		HIV Protease Infection
    JE-2178 is an orally available HIV-1 protease inhibitor with IC50 and Ki values are 15 and 0.318 nM respectively. JE-2178 has antiviral activity .
    JE-2178
  • HY-122453
    Palinavir

    		HIV Protease Infection
    Palinavir is a potent human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) protease inhibitor with an IC50 of 0.5-30 nM . Palinavir has antiviral activity .
    Palinavir
  • HY-155308
    SARS-CoV-2-IN-61

    		SARS-CoV Infection
    SARS-CoV-2-IN-61 (compound 8i) is a SARS CoV-2 PLpro inhibitor with an IC50 of 16 µM. SARS-CoV-2-IN-61 has antiviral activities .
    SARS-CoV-2-IN-61
  • HY-110039
    BIBX 1382 dihydrochloride

    		EGFR Infection
    BIBX 1382 dihydrochloride is an ErbB kinase inhibitor with significant antiviral activity. BIBX 1382 affects the ability of viruses to enter host cells by inhibiting members of the ErbB kinase family. It can be used to study the interaction mechanism between virus and host and the broad spectrum intervention of highly pathogenic viruses .
    BIBX 1382 dihydrochloride
  • HY-149774
    GC-78-HCl

    		SARS-CoV Infection
    GC-78-HCl is an orally and nonpeptidic SARS-CoV-2 M pro inhibitor, with an IC50 of 0.19 μM for enzyme. GC-78-HCl has excellent antiviral activity and favorable pharmacokinetic properties .
    GC-78-HCl
  • HY-154990
    RdRP-IN-7

    		DNA/RNA Synthesis SARS-CoV Infection
    RdRP-IN-7 is a RNA-dependent RNA polymerase (RdRp) inhibitor that shows the inhibition of SARS-CoV-2 infection with an IC50 of 8.2 μM, an IC90 of 14.1 μM and an CC90 of 79.1 μM. RdRP-IN-7 can be used for antiviral research .
    RdRP-IN-7
  • HY-174258
    ATPase-IN-6

    		Proton Pump HIV SARS-CoV Infection
    ATPase-IN-6 is a H +/K +- ATPase inhibitor and a prazole derivative. ATPase-IN-6 has significant antiviral activity against multiple viruses, such as HIV-1 and SARS-COV2. ATPase-IN-6 can be used for antiviral infections research .
    ATPase-IN-6
  • HY-162229
    GRL-190-21

    		SARS-CoV Infection
    GRL-190-21 (compound 5e) is an inhibitor for SARS-Cov-2-Mpro with a Ki of 0.04 nM and exhibits antiviral activity in VeroE6 cells with EC50 of 0.26 μM. GRL-190-21 reduces the infectivity, replication, and cytopathic effect of SARS-CoV-2 without significant toxicity .
    GRL-190-21
  • HY-150625
    SARS-CoV-2 nsp13-IN-4

    		DNA/RNA Synthesis SARS-CoV Infection
    SARS-CoV-2 nsp13-IN-4 (C4 (d)) is a potent and selective nsp13 helicase small-molecule inhibitor and inhibit the ssDNA+ ATPase activity of nsp13 with an IC50 value of 57 μM. SARS-CoV-2 nsp13-IN-4 is agentlike molecule with molecular weight of less than 450Da and can provide a broad-spectrum antiviral effect .
    SARS-CoV-2 nsp13-IN-4
  • HY-159879
    AAK1-IN-6

    		AAK1 Dengue Virus Infection
    AAK1-IN-6 (Compound 23) is an inhibitor of AP-2-associated protein kinase 1 (AAK1, IC50 = 12 nM) with antiviral activity against the dengue virus (DNEV2, EC50 = 0.24 μM) and Venezuelan equine encephalitis virus (VEEV, EC50 = 0.30 μM). AAK1-IN-6 can be utilized in antiviral research .
    AAK1-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: